Member Info for Fanti

Here we go. :) Deal.

I cannot think of a contract that neglect such a main aspect as pointed out by BB No.3. Sure SO has to hand 737 back incl their patents recorded thus being reimbursed by a lump sum for their achievements in the event those were put on hold or not taken any further. Anything else was daft if there were no condition agreed on as to guarantee the development at all and also development in a certain period of time.

Should have said Unless they are on their holidays.

I think it was nice if the BOD get sorted this year meaning if they finally approached any preferred institution for CTA. One more week left to apply online and to indicate job done by an RNS.
Unlike they are not on their X-mas holidays that was the right thing to do and confirm the willing
and effort to also satisfy investor interests.
Now guys what hinders you to eventually move on?

Really looks like the body is way behind indeed. The following trial was published 13th Dec.

The study of SCRT+CAPOX vs SCRT+CAPOXIRI for locally advanced rectal cancer
ICH-GCP > News - 13 Dec 14:27
...
The clinical trial started in November 21, 2022 and will continue throughout December 31, 2030.

For more details: https://ichgcp.net/clinical-trials-registry/NCT05646511.

I am here invested for years and not a victim at all, I'm afraid.
Thing is I can read RNS. I appreciate the bullet points on what we have and have achieved so far. Facts we can look at and trust since made public.

CTA has not yet been rejected. On the bright side we await approval, don't we? No point to ignore submission in a first place. Right?

Facts are much appreciated. Cheers mate. Keep up the good work, Ahfam.

You may have missed so far the strategy. Sareum not really for sale me thinks.

Our strategy
Sareum’s strategy is to develop programmes to late preclinical or early clinical stages before licensing or partnering.

Sareum is a clinical stage small molecule drug development company which is focused on advancing molecules in the JAK kinase family into clinical development for autoimmune disease and cancer. It is led by a highly experienced team with expertise in kinase inhibition and decades of experience in R&D and public company management.

Sareum’s pipeline is focused on the TYK/JAK signalling family, which is critical for maintaining a healthy immune system. The JAK kinase family is an area of growing scientific and commercial focus, with strong clinical validation in psoriasis and psoriatic arthritis.

Our approach is to discover and develop programmes to late preclinical or early clinical stages before licensing or partnering. This allows us to maximise the return on our investment.

We maintain a lean cost base with a small, highly specialised team and use trusted third-party providers to maximise return on investment.

.. Being a cynic, the more shares issued would then allow Sareum to be controlled by institutions as opposed to private investors. ..

What was the story again with the HNWI? They are entiteled to top up up which would help in any case.

My apologies. the previous to being deleted. I got s.th wrong.

Looks like the whole monday discussion has been destroyed.
But
Thank god comments from Spurs and Lazarus and the likes are safe.

RNS from 8th Noc
Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: “We are surprised and disappointed by this response. We believe Sareum made a compelling case to the regulatory authority with a robust non-clinical data package, generated in collaboration with world-leading, internationally recognised CROs, to support our application. We are committed to getting clarification on next steps.”

Something is on. Data submitted can corrupt but CtA should have been rejected in this case by now.
Why is MHRA making no move.?
Are they on their holidays fair enough or is the institution partly as corrupt as people in the european government are?

On what occasion did SAR fail to update the shareholders again, even though they said they would?
I may have missed that failure hence I am very confident and calm. Am I Mistaken? Thks backing up.

Frankly, I was wondering this morning if MHRA was possibly sponsored by big phrma, is run by government though.
No bribe but pharma lobby with an impact still me thinks.

Plunging share price is easy once one dump up to a 500k shares worth to a minimum price asked. No rocket science to understand the pattern.

Rightly so many people on this BB have insider information. There is or was WIP with insider information re 737, Lazarus got a source re internal proceedings at MHRA and last but not least same has Spurs as we now may presume. Who and what to believe really other than Sareum and the BOD?
I remember WIPs job well done with the share price rocketing lately in anticipation of SRA727 and partnering with GSK. Now we change assumption and direction. Great trouble and doubts in SAR and its pipeline because of CTA delay.

Sooner or later Pharma are desperate for our molecules. And we have got them and the compounds patensed. Oh YEAH! that should be good and marerialize in revenue $$$$

The question simply is what can one do once you depend on a 3rdP to keep going?

Some of my shares are now for sale. I have price tagged them 4.00£.

Not sure if such an action really is helpful to stabilise the price though. The idea is MM cannot play games with them.